Cargando…

Development of DOTA-Rituximab to be Labeled with (90)Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma

NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johari doha, Fariba, Rahmani, Siyavash, Rikhtechi, Pedram, Rasaneh, Samira, Sheikholislam, Zahra, Shahhosseini, Soraya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Shaheed Beheshti University of Medical Sciences 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603870/ https://www.ncbi.nlm.nih.gov/pubmed/28979315

Ejemplares similares

Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with (90)Y and (111)In for domestic radioimmunotherapy and radioscintigraphy of Non-Hodgkin’s Lymphoma
por: Gholipour, Nazila, et al.
Publicado: (2014)

Preparation & in vitro evaluation of (90)Y-DOTA-rituximab
por: Kameswaran, Mythili, et al.
Publicado: (2016)

An approach for conjugation of (177)Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients
por: Thakral, Parul, et al.
Publicado: (2014)

A convenient Simple Method for Synthesis of Meta-iodobenzylguanidine (MIBG)
por: Sheikholislam, Zahra, et al.
Publicado: (2013)

Standard Operating Procedure for In-house Preparation of (131)I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Pickford, Matthew D., et al.
Publicado: (2012)

Experimental α-particle radioimmunotherapy of breast cancer using (227)Th-labeled p-benzyl-DOTA-trastuzumab
por: Abbas, Nasir, et al.
Publicado: (2011)

Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Calais, Phillipe J., et al.
Publicado: (2012)

Novel and Efficient Method for Solid Phase Synthesis of Urea-Containing Peptides Targeting Prostate Specific Membrane Antigen (PSMA) in Comparison with Current Methods
por: Mosayebnia, Mona, et al.
Publicado: (2018)

Influence of DOTA Chelators on Radiochemical Purity and Biodistribution of (177)Lu- and (90)Y-Rituximab in Xenografted Mice
por: Karczmarczyk, Urszula, et al.
Publicado: (2018)

Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma
por: Bodet-Milin, Caroline, et al.
Publicado: (2013)

Alpha radioimmunotherapy using (225)Ac-proteus-DOTA for solid tumors - safety at curative doses
por: Cheal, Sarah M., et al.
Publicado: (2020)

In Vitro Characterization of (177)Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer
por: Mohajershojai, Tabassom, et al.
Publicado: (2022)

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
por: Muylle, Kristoff, et al.
Publicado: (2015)

Physiologically Based Pharmacokinetic Modeling Is Essential in (90)Y-Labeled Anti-CD66 Radioimmunotherapy
por: Kletting, Peter, et al.
Publicado: (2015)

Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy
por: Kesavan, Murali, et al.
Publicado: (2017)

Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
por: Buchegger, Franz, et al.
Publicado: (2011)

Preparation and Biological Study of (68)Ga-DOTA-alendronate
por: Fakhari, Ashraf, et al.
Publicado: (2016)

Therapeutic efficacy evaluation of radioimmunotherapy with (90)Y‐labeled anti‐podoplanin antibody NZ‐12 for mesothelioma
por: Sudo, Hitomi, et al.
Publicado: (2019)

Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin’s lymphoma
por: Andemariam, Biree, et al.
Publicado: (2007)

Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma
por: Ludwig, Andrew D., et al.
Publicado: (2019)

Development of [(225)Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration
por: Hull, Ashleigh, et al.
Publicado: (2023)

Radioimmunotherapy of Non-Hodgkin’s Lymphoma: From the ‘Magic Bullets’ to ‘Radioactive Magic Bullets’
por: Chamarthy, Murthy R., et al.
Publicado: (2011)

Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar
por: Sachpekidis, Christos, et al.
Publicado: (2019)

In vitro characterisation of [(177)Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer
por: Hull, Ashleigh, et al.
Publicado: (2023)

Clearance of yttrium-90-labelled anti-tumour antibodies with antibodies raised against the 12N4 DOTA macrocycle.
por: Casey, J. L., et al.
Publicado: (1998)

Evaluation of Efficacy of Radioimmunotherapy with (90)Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models
por: Sugyo, Aya, et al.
Publicado: (2015)

Radioimmunotherapy of pancreatic cancer xenografts in nude mice using (90)Y-labeled anti-α(6)β(4) integrin antibody
por: Aung, Winn, et al.
Publicado: (2016)

Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin’s lymphoma
por: Burdick, Michael J, et al.
Publicado: (2009)

Radioimmunotherapy-based conditioning regimen prior to autologous stem cell transplantation in non-Hodgkin lymphoma
por: Eskian, Mahsa, et al.
Publicado: (2018)

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma
por: Herrera, Alex F., et al.
Publicado: (2021)

Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Hauptrock, Beate, et al.
Publicado: (2008)

Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study
por: Grana, C, et al.
Publicado: (2002)

Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target
por: Sabanathan, Dhanusha, et al.
Publicado: (2021)

Labelling of (90)Y- and (177)Lu-DOTA-Bioconjugates for Targeted Radionuclide Therapy: A Comparison among Manual, Semiautomated, and Fully Automated Synthesis
por: Iori, Michele, et al.
Publicado: (2017)

Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy
por: Gritti, Giuseppe, et al.
Publicado: (2018)

Immunostimulatory effects of radioimmunotherapy
por: Constanzo, Julie, et al.
Publicado: (2022)

Dynamic Metabolic Changes during the First 3 Months after (90)Y-Ibritumomab Tiuxetan Radioimmunotherapy
por: Takahashi, Miwako, et al.
Publicado: (2014)

Radioimmunotherapy of human hepatocellular carcinoma xenografts with 131I-labelled antiferritin antibody.
por: Saiful Alam, A. F.
Publicado: (1991)

Radioimmunotherapy with an (211)At‐labeled anti–tissue factor antibody protected by sodium ascorbate
por: Takashima, Hiroki, et al.
Publicado: (2021)

Radioimmunotherapy study of (131)I-labeled Atezolizumab in preclinical models of colorectal cancer
por: Zhang, Linhan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8b1buls1hc7g7d7ja7psvtoi92